STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. 2007

Ulrike von Arnim, and Ulrich Peitz, and Bettina Vinson, and Karl-Josef Gundermann, and Peter Malfertheiner
Otto-von-Guericke-Universität Magdeburg, Zentrum für Innere Medizin, 39120 Magdeburg, Germany.

BACKGROUND Functional dyspepsia (FD) constitutes a complex picture with a variety of epigastric symptoms. No standard therapy is currently available for FD. OBJECTIVE This multicenter, placebo-controlled, double-blind study evaluated the efficacy and tolerability of the herbal drug STW 5, mainly comprising a fresh plant extract from Iberis amara. METHODS Patients with FD were included. Gastrointestinal endoscopy, H. pylori-status, and a 7-day run-in phase were required. A total of 315 patients were treated with 3 x 20 drops/day of either STW 5 or placebo. Symptom assessment: day 0, 2, 4, and 8 wk of treatment. The principal outcome criterion was the change in a validated Gastrointestinal Symptom Score (GIS). Symptom severity was rated using the Likert scale. RESULTS A total of 315 patients remained in the safety population. Of them, 158 were treated with STW 5 and 157 with placebo. The intention-to-treat population comprised 308 patients. Dropout number was similar in both groups. GIS showed improvement during the treatment period. The STW 5 group improved 6.9+/-4.8 points up to day 56, placebo group by 5.9+/-4.3 (P<0.05). H. pylori did not influence the results. Drug tolerability and safety were similar in both groups. CONCLUSIONS This placebo-controlled study with an 8-wk treatment period documents the efficacy of STW 5 in FD.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010936 Plant Extracts Concentrated pharmaceutical preparations of plants obtained by removing active constituents with a suitable solvent, which is evaporated away, and adjusting the residue to a prescribed standard. Herbal Medicines,Plant Extract,Extract, Plant,Extracts, Plant,Medicines, Herbal
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D004415 Dyspepsia Impaired digestion, especially after eating. Indigestion,Dyspepsias,Indigestions
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012449 Safety Freedom from exposure to danger and protection from the occurrence or risk of injury or loss. It suggests optimal precautions in the workplace, on the street, in the home, etc., and includes personal safety as well as the safety of property. Safeties
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Ulrike von Arnim, and Ulrich Peitz, and Bettina Vinson, and Karl-Josef Gundermann, and Peter Malfertheiner
May 2024, JGH open : an open access journal of gastroenterology and hepatology,
Ulrike von Arnim, and Ulrich Peitz, and Bettina Vinson, and Karl-Josef Gundermann, and Peter Malfertheiner
January 1987, Clinical therapeutics,
Ulrike von Arnim, and Ulrich Peitz, and Bettina Vinson, and Karl-Josef Gundermann, and Peter Malfertheiner
November 2023, Journal of digestive diseases,
Ulrike von Arnim, and Ulrich Peitz, and Bettina Vinson, and Karl-Josef Gundermann, and Peter Malfertheiner
August 2022, Neurogastroenterology and motility,
Ulrike von Arnim, and Ulrich Peitz, and Bettina Vinson, and Karl-Josef Gundermann, and Peter Malfertheiner
October 2021, Middle East journal of digestive diseases,
Ulrike von Arnim, and Ulrich Peitz, and Bettina Vinson, and Karl-Josef Gundermann, and Peter Malfertheiner
July 2020, Medicina (Kaunas, Lithuania),
Ulrike von Arnim, and Ulrich Peitz, and Bettina Vinson, and Karl-Josef Gundermann, and Peter Malfertheiner
January 2004, Digestion,
Ulrike von Arnim, and Ulrich Peitz, and Bettina Vinson, and Karl-Josef Gundermann, and Peter Malfertheiner
November 2012, World journal of gastroenterology,
Ulrike von Arnim, and Ulrich Peitz, and Bettina Vinson, and Karl-Josef Gundermann, and Peter Malfertheiner
October 2007, Zeitschrift fur Gastroenterologie,
Ulrike von Arnim, and Ulrich Peitz, and Bettina Vinson, and Karl-Josef Gundermann, and Peter Malfertheiner
July 2014, Neurogastroenterology and motility,
Copied contents to your clipboard!